Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 329-333

  DeMagalhaes Silverman, M ^a,b   Bloom, E J ^a   Donnenberg, A ^a   Lister, J ^a   Pincus, S ^a   Rybka, W B ^a   Ball, E D ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Busulfan; Cyclophosphamide conditioning regimen; Hematologic malignancies

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MEPREDNISONE; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; T LYMPHOCYTE; THROMBOCYTE; VEIN OCCLUSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PNEUMONIA; RISK FACTORS; VASCULAR DISEASES;

EID: 0029966382     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Thomas ED. Marrow transplantation for malignant diseases (Kamofsky Memorial Lecture). J Clin Oncol 1983; 1: 517-531.
2. Santos GW, Tutschka PJ. Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
3. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987: 70: 1382-1388.
4. 2. Blood 1991; 78: 838-843.
5. 2): an update. Semin Oncol 1993; 20 (Suppl. 4): 27-31.
6. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
7. Ball ED, Mills LE, Coughlin CT et al. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid cell-specific monoclonal antibodies. Blood 1986; 68: 1311-1315.
8. Wagner JE, Donnenberg AD. Noga SJ et al. Lymphocyte depletion of donor marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 1988; 72: 1168-1176.
9. Glucksberg R, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
10. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570.
11. 2. Blood 1992; 80: 1352-1357.
12. Morgan M, Dodds A, Atkinson K et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991: 77: 529-534.
13. Atkinson K, Biggs J, Noble G et al. Preparative regimens for marrow transplantation containing busulfan are associated with hemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leukopenia and little oro-pharyngeal mucositis. Bone Marrow Transplant 1987; 2: 385-394.
14. Jones RJ, Lee KSK, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
15. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603-608.
16. Essel JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784-2788.
17. Arthur RR, Shah KV, Baust SJ et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. New Engl J Med 1986; 315: 230-234.
18. Labopin M, Gorin NC. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. Leukemia 1992; 6 (Suppl. 4): 95-99.
19. Rowley SD, Jones RJ, Piantadosi S et al. Efficacy of ex vivo purging for autologous bone marrow transplantation with treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501-506.
20. Solderling CCB, Song CW, Blazar BR, Vallera DA. A correlation between conditioning and engraftment in recipients of MHC-mismatched T-cell depleted murine bone marrow transplants. J Immunol 1985; 135: 941-946.
21. Uharek L, Gassman W. Glass B et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplant. Blood 1992; 79: 1612-1621.
22. Sahebi F, Bolwell B, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high dose busulfan and cyclophosphamide (BU/CY) conditioning regimen. Blood 1993; 82: (Suppl. 1): 314 (abstr.).